ART899, a derivative of ART558 is a potent, specific allosteric inhibitor of DNA polymerase theta (Polθ), specifically inhibits Polθ MMEJ activity with IC50 of 180 nM. It specifically radiosensitizes tumor cells and have a potent stand-alone antitumor effect in cancer cells.

ART899, a derivative of ART558 is a potent, specific allosteric inhibitor of DNA polymerase theta (Polθ), specifically inhibits Polθ MMEJ activity with IC50 of 180 nM. It specifically radiosensitizes tumor cells and have a potent stand-alone antitumor effect in cancer cells.

ART899, a derivative of ART558 is a potent, specific allosteric inhibitor of DNA polymerase theta (Polθ), specifically inhibits Polθ MMEJ activity with IC50 of 180 nM. It specifically radiosensitizes tumor cells and have a potent stand-alone antitumor effect in cancer cells.

HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans.

HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans.

HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans.

HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans.

PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein.

PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein.

PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein.